Roche quarterly sales drop amid healthcare curbs

Roche Holding AG on Thursday kick off the European pharmaceutical industry’s reporting season with a 9% drop in first-quarter sales, hit by global drug price cuts, declining sales of its blockbuster cancer drug Avastin, and by volatile currency markets.